posted on 2021-07-20, 13:43authored byGabriela Farias Quipildor, Kai Mao, Pedro J. Beltran, Nir Barzilai, Derek M. Huffman
Similar to insulin,
central administration of insulin-like Growth Factor-1 (IGF-1) can suppress hepatic
glucose production (HGP), but it is unclear if this effect is mediated via
insulin receptors (InsRs) or IGF-1 receptors (IGF-1Rs) in the brain. To this
end, we utilized pharmacologic and genetic approaches in combination with hyperinsulinemic-euglycemic
clamps to decipher the role of these receptors in mediating central effects of IGF-1
and insulin on HGP. In rats, we observed that intracerebroventricular (ICV)
administration of IGF-1 or insulin markedly increased the glucose infusion rate
(GIR) by >50% and suppressed HGP (P<0.001). However, these effects
were completely prevented by preemptive ICV infusion with an IGF-1R and
InsR/IGF-1R Hybrid (HybridRs) blocking antibody.
Likewise, ICV infusion of the InsR antagonist, S961, which also can bind HybridRs,
interfered with the ability of central insulin, but not IGF-1 to increase the
GIR. Furthermore, hyperinsulinemic clamps in mice lacking IGF-1Rs in AgRP
neurons revealed ~30% reduction in the GIR in KO animals, which was explained
by an impaired ability of peripheral insulin to completely suppress HGP (P<0.05).
Signaling studies further revealed an impaired ability of peripheral insulin to
trigger ribosomal S6 phosphorylation or PIP3 production in AgRP neurons lacking
IGF-1Rs. In summary, these data suggest that attenuation of IGF-1Rs signaling in
the MBH, and specifically in AgRP neurons, can phenocopy impaired regulation of
HGP as previously demonstrated in mice lacking InsRs in these cells, suggesting
a previously unappreciated role for IGF-1Rs and/or HybridRs in the regulation
of central insulin/IGF-1 signaling on glucose metabolism.
Funding
This work was supported by R00 AG037574; and Einstein Startup Funds to D.M.H. DMH was also a recipient of an American Federation for Aging Research (AFAR) junior faculty award while conducting this work. This study was also supported by R37 AG018381 and the Einstein Nathan Shock Center (P30 AG038072) to N.B. and the Einstein-Sinai Diabetes Research Center (P30 DK020541). We would also like to acknowledge support from the NCI supported Einstein Cancer Center (P30 CA013330). Einstein Analytical Imaging Core use was supported by NIH SIG awards (#1S10OD019961-01; 1S10OD023591-01).